T1	Participants 61 116	bone metastases in patients with advanced breast cancer
T3	Participants 453 689	Patients were randomly assigned to receive either subcutaneous denosumab 120 mg and intravenous placebo (n = 1,026) or intravenous zoledronic acid 4 mg adjusted for creatinine clearance and subcutaneous placebo (n = 1,020) every 4 weeks
T2	Participants 325 430	delaying or preventing skeletal-related events (SREs) in patients with breast cancer with bone metastases
